Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson’s Disease: Implications for Neurodegeneration
Cellular and Molecular Neurobiology · 22.10.2025 · 45 (1)
DOI: 10.1007/s10571-025-01609-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular and Molecular Neurobiology, online erschienen am 22.10.2025. Verfasst von Abinash Ravi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Department of Medical Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences…. Hauptthemen laut MEDLINE: Parkinson Disease, Fatty Acids, Volatile, Nerve Degeneration, Neurodegenerative Diseases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Neurodegeneration involves the progressive deterioration of neuronal structure and function, leading to deficits in cognition, motor skills, and other neurological processes. Parkinson's disease (PD) is notably prevalent among neurodegenerative disorders, characterized by dopaminergic neurodegeneration, protein misfolding, and an inflammatory brain environment. Despite advancements in understanding its pathophysiology, PD and other neurodegenerative conditions still lack effective disease-modifying therapies. This shortfall highlights the need for novel, multifactorial approaches to treatment. Recent research has spotlighted the gut-brain axis as a significant player in neurological health, particularly through the activity of gut-derived short-chain fatty acids (SCFAs). These microbial metabolites, primarily acetate, propionate, and butyrate, are produced via the fermentation of dietary fibers and are vital for maintaining intestinal and neural homeostasis. SCFAs exert anti-inflammatory effects, preserve blood-brain barrier integrity, and modulate neurotransmitter systems. Among them, butyrate shows notable neuroprotective capabilities, including histone deacetylase inhibition and mitochondrial enhancement. Disruption in SCFA production has been associated with PD progression, further underscoring their relevance. This review explores the mechanistic roles of SCFAs in modulating neurodegeneration, with an emphasis on PD. SCFA-based strategies offer a promising adjunctive route to restoring microbial balance, mitigating neuroinflammation, and safeguarding neurological function in neurodegenerative disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology, Department of Medical Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, 602 105, India.
- Institute of Biotechnology, Department of Medical Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, 602 105, India. ieshitapan.sse@savee…
Zitieren
APA
Ravi, A., Umapathy, S., & Pan, I. (2025). Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson’s Disease: Implications for Neurodegeneration. Cellular and Molecular Neurobiology, 45(1). https://doi.org/10.1007/s10571-025-01609-2
Vancouver
Ravi A, Umapathy S, Pan I. Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson’s Disease: Implications for Neurodegeneration. Cellular and Molecular Neurobiology. 2025;45(1). doi:10.1007/s10571-025-01609-2
BibTeX
@article{Ravi2025,
author = {Ravi, Abinash and Umapathy, Suganiya and Pan, Ieshita},
title = {Short-Chain Fatty Acids as a Therapeutic Strategy in Parkinson’s Disease: Implications for Neurodegeneration},
journal = {Cellular and Molecular Neurobiology},
year = {2025},
volume = {45},
number = {1},
doi = {10.1007/s10571-025-01609-2}
}
EUVIMED